使用MutaMouse模型对生殖细胞突变的时间分析支持经合组织测试指南488中建议的设计
Gu Zhou1, Andrew Williams1, Danielle P M LeBlanc1
1Environmental Health Science and Research Bureau, Healthy Environments and Consumer Safety Branch, 251 Sir Frederick Banting Driveway, Ottawa, Health CanadaON, K1A 0K9, Canada.
Archives of toxicology
|May 21, 2025
概括
经济合作与发展组织的测试指南488 (TG 488) 使用28+28天的暴露和采样设计来评估生殖细胞的致病性. 这项研究发现不需要更晚的采样时间,支持当前的TG 488设计.
科学领域:
- 毒理学 毒理学 毒理学
- 遗传学 遗传学 是一个
- 在体内进行突变性试验.
背景情况:
- 经济合作与发展组织的测试指南 (TG 488) 是使用转基因动物模型评估体内突变性的一种标准.
- TG 488建议28天暴露,然后在28天后 (28+28d) 采取生殖细胞样本.
研究的目的:
- 评估是否需要比TG 488中的标准28+28d更长的采样时间来评估生殖细胞变异性.
- 确定胚胎细胞突变性评估的最佳实验设计.
主要方法:
- 成年 MutaMouse雄性被口服暴露于甲 (BaP),N-乙烯-N-氨酸urea (ENU),异甲硫酸盐 (iPMS),或prokarbazine (PRC) 的28天.
- 基因细胞的突变频率 (MF) 通过lacZ测定在暴露后的3,28,42和70天被量化.
- 使用基准剂量建模来分析剂量反应关系.
主要成果:
- 所有四种测试化学物质都在28+28d采样时间显著增加了lacZ MF.
- 在以后的采样时间 (42d和70d) 没有观察到MF的进一步增加.
- 发现28+28d设计足够,一些化学品在这个时间点表现出比较早的采样 (3d) 更强烈的反应.
结论:
- 在TG 488中标准的28+28d实验设计足以评估生殖细胞的变异性.
- 暴露后28天以后的采样时间不必用于根据TG 488.8评估生殖细胞变异性.
- 这些发现支持继续使用已建立的TG 488协议.
相关概念视频
In-vitro Mutagenesis
13.7K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
13.7K
Mouse Models of Cancer Study
5.5K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.5K
Mutagenicity and Carcinogenicity
1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K


